Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation

This study is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial. Subjects will be recipients of allogeneic hematopoietic stem cell transplantation, with a planned enrollment of 9 to 18 subjects, to evaluate the safety and efficacy of JYEST cell injection for the prevention of EBV infection after allogeneic hematopoietic stem cell transplantation.

NCT Number	NCT07476014
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment	18 participants
Start Date	2026-02-28
Primary Completion	2029-01-01 (estimated)
Study Completion	2029-02-27 (estimated)
Updated on ClinicalTrials.gov	2026-03-17